Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse

[1]  P. Nelson,et al.  Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy , 2019, Nature Cell Biology.

[2]  P. Lønning,et al.  NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients , 2018, Breast Cancer Research.

[3]  C. Hudis,et al.  Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer , 2018, Clinical Breast Cancer.

[4]  C. Perou,et al.  Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel , 2018, Clinical Cancer Research.

[5]  T. Stokowy,et al.  Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients , 2018, Translational oncology.

[6]  K. Pantel,et al.  Disseminated breast tumour cells: biological and clinical meaning , 2018, Nature Reviews Clinical Oncology.

[7]  Michael R. Padgen,et al.  Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments , 2017, Nature Cell Biology.

[8]  Rainer Spang,et al.  Early dissemination seeds metastasis in breast cancer , 2016, Nature.

[9]  U. Jeschke,et al.  Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients , 2016, Oncology.

[10]  K. White,et al.  Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing , 2016, Genome Biology.

[11]  U. Jeschke,et al.  Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets , 2016, Journal of Cancer Research and Clinical Oncology.

[12]  L. Pusztai,et al.  Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer , 2015, Clinical Cancer Research.

[13]  S. Tavazoie,et al.  Identification of Molecular Determinants of Primary and Metastatic Tumor Re-Initiation in Breast Cancer , 2015, Nature Cell Biology.

[14]  T. Fehm,et al.  Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis. , 2014, European journal of cancer.

[15]  B. Naume,et al.  Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients , 2014, BMC Cancer.

[16]  T. Fehm,et al.  The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse , 2013, Breast Cancer Research and Treatment.

[17]  Massimo Cristofanilli,et al.  Considerations in the development of circulating tumor cell technology for clinical use , 2012, Journal of Translational Medicine.

[18]  M. Ellis,et al.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.

[19]  A. Gown,et al.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. , 2008, Clinical breast cancer.

[20]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[21]  Tanja Fehm,et al.  Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance , 2008, Breast Cancer Research.

[22]  L. Ylagan,et al.  Isolation and Molecular Profiling of Bone Marrow Micrometastases Identifies TWIST1 as a Marker of Early Tumor Relapse in Breast Cancer Patients , 2007, Clinical Cancer Research.

[23]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[24]  M. Watson,et al.  Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease , 2012, Breast Cancer Research and Treatment.

[25]  M. Lippman,et al.  Breast Cancer Research and Treatment , 2004, Breast Cancer Research and Treatment.

[26]  H Sommer,et al.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.